Risk models in genetic epidemiology
- PMID: 11308072
- DOI: 10.1177/096228020000900605
Risk models in genetic epidemiology
Abstract
Advances in the identification and treatment of genetically transmitted diseases have lead to an increased need for reliable estimates of genetic susceptibility risk. These estimates are used in clinic settings to identify individuals at increased risk of being a carrier of a disease susceptibility allele as well as to define the probability of developing a particular disease given one is a carrier. Accurate assessment of these probabilities is extremely important given the implications for medical decision making including the identification of patients who might benefit from genetic counselling or from entry into clinical trials. A wide range of risk models has been proposed including those that utilize logistic regression, Cox proportional hazards regression, log-incidence models, and Bayesian modelling. The specific data used to create the various risk models varies by disease and may include molecular, epidemiologic, and clinical information although, in general, family history remains the primary variable of interest, particularly for those diseases for which a susceptibility allele(s) has yet to be identified. When permitted by sample size, researchers also attempt to measure the effect of any gene-environment interaction. In this paper we give an overview of the various definitions of risk as well as several of the more frequently used methods of risk estimation in genetic epidemiology at present. In addition, the means by which different methods are able to provide a measure of error or uncertainty associated with a given risk estimate will be discussed. Applications to risk modelling for breast cancer are given the disease for which risk assessment has probably been most extensively defined.
Similar articles
-
Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians.Fam Cancer. 2001;1(3-4):197-206. doi: 10.1023/a:1021135807900. Fam Cancer. 2001. PMID: 14574179 Review.
-
Clinical application of breast cancer risk assessment models.Future Oncol. 2010 Mar;6(3):355-65. doi: 10.2217/fon.10.5. Future Oncol. 2010. PMID: 20222793 Review.
-
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11. J Clin Oncol. 2003. PMID: 12692171
-
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.Breast Cancer Res. 2006;8(1):R3. doi: 10.1186/bcr1365. Epub 2005 Dec 12. Breast Cancer Res. 2006. PMID: 16417652 Free PMC article.
-
Limited family structure and BRCA gene mutation status in single cases of breast cancer.JAMA. 2007 Jun 20;297(23):2587-95. doi: 10.1001/jama.297.23.2587. JAMA. 2007. PMID: 17579227
Cited by
-
Informing Women and Their Physicians about Recommendations for Adjunct Breast MRI Screening: A Cohort Study.Health Commun. 2018 Apr;33(4):489-495. doi: 10.1080/10410236.2016.1278499. Epub 2017 Feb 3. Health Commun. 2018. PMID: 28157381 Free PMC article.
-
Improving the diagnostic accuracy of a stratified screening strategy by identifying the optimal risk cutoff.Cancer Causes Control. 2019 Oct;30(10):1145-1155. doi: 10.1007/s10552-019-01208-9. Epub 2019 Aug 3. Cancer Causes Control. 2019. PMID: 31377875 Free PMC article.
-
Principles in genetic risk assessment.Ther Clin Risk Manag. 2005 Mar;1(1):15-20. doi: 10.2147/tcrm.1.1.15.53606. Ther Clin Risk Manag. 2005. PMID: 18360538 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources